Company intelligence / Profile preview
Yingli Pharma
Shanghai, Shanghai, Chinayl-pharma.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Linperlisib has been approved in China for r/r follicular lymphoma treatment since 2022. The company recently received FDA clearance to initiate a global Phase 3 study of linperlisib for relapsed/refractory peripheral T-cell lymphoma. More than 6,000 patients have been treated with linperlisib in clinical trials and post-market approval, including more than 165 r/r PTCL patients across China, the US, and Europe, demonstrating a consistent and well-tolerated safety profile[1][3].
- Therapeutic areas
- OncologyNephrologyRheumatology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
MD Anderson
Beyond the preview
Go deeper on Yingli Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yingli Pharma.